Epclusa receives FDA approval with HCV/HIV Coinfection
Tig said
Aug 2, 2017
Gilead Sciences announced the FDA approval of Epclusa for the treatment of hepatitis C genotypes 1 through 6 in patients coinfected with HIV, according to a press release.
“Epclusa has already helped further simplify HCV treatment among mono-infected patients, and we are pleased that HCV/HIV coinfected patients can benefit from this pan-genotypic single tablet regimen,” John F. Milligan, PhD, president and CEO of Gilead Sciences, said in the release. “This approval advances the commitment we’ve made to the HCV and HIV communities to deliver innovative new treatments that address their unmet medical needs.”
Gilead Sciences announced the FDA approval of Epclusa for the treatment of hepatitis C genotypes 1 through 6 in patients coinfected with HIV, according to a press release.
“Epclusa has already helped further simplify HCV treatment among mono-infected patients, and we are pleased that HCV/HIV coinfected patients can benefit from this pan-genotypic single tablet regimen,” John F. Milligan, PhD, president and CEO of Gilead Sciences, said in the release. “This approval advances the commitment we’ve made to the HCV and HIV communities to deliver innovative new treatments that address their unmet medical needs.”
Epclusa HCV/HIV Approval